Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05896527 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

A Phase 2 study of Plaque Psoriasis, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.

Completed
Registry status
Phase 2
Development phase
229
Enrollment target
20
Study locations

NCT05896527 is a Phase 2 study of Plaque Psoriasis that has completed, run by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. The registered enrollment target is 229 participants, below the 411-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05896527, a Phase 2 study of Plaque Psoriasis, has completed, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.

COMPLETED
Registry status
Phase 2
Development phase
229 participants
Enrollment target
20
Study locations

Study Summary

This was a 12-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of DC-806 in participants with moderate to severe plaque psoriasis. This study evaluated the efficacy, safety, tolerability, and pharmacokinetics (PK) of multiple oral doses of DC-806 in participants with moderate to severe plaque psoriasis.

Conditions Studied

Plaque Psoriasis

Interventions

  • OTHER Placebo
  • DRUG DC-806

Study Locations (20)

Florida

  • Driven Research LLC - Coral Gables
  • Kirsch Dermatology - Probity - PPDS - Naples
  • GCP Global Clinical Professionals, LLC - St. Petersburg
  • ForCare Clinical Research - CenExel FCR - PPDS - Tampa

Ontario

  • CCA Medical Research - Probity - PPDS - Ajax
  • SimcoDerm Medical and Surgical Dermatology Centre - Probity - PPDS - Barrie
  • Dermatrials Research - Hamilton
  • Lynderm Research Inc. - Probity - PPDS - Markham

California

  • First OC Dermatology - Fountain Valley
  • Clinical Science Institute - Santa Monica

Indiana

  • The Indiana Clinical Trials Center, PC - Plainfield

Kentucky

  • Dermatology Specialists Research - 501 S 2nd St - Louisville

New York

  • DICE Therapeutics Study Site - New York

Ohio

  • Dermatologists of Southwest Ohio - Probity - PPDS - Mason

Pennsylvania

  • Paddington Testing Company Inc - Philadelphia

Trial Details

FieldValue
Enrollment Target 229 participants
Start Date 2023-05-02
Est. Completion 2024-03-25
Phase Phase 2

Sponsor

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05896527

The ClinicalTrials.gov registry entry for NCT05896527 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 411-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (44% lower). The listed sponsor is DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05896527 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Ontario, California.

Frequently Asked Questions

What is clinical trial NCT05896527 about?

NCT05896527 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis". This was a 12-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of DC-806 in participants with moderate to severe plaque psoriasis. This study evaluated the efficacy, safety, tolerability, and pharmacokin...

What is the current status of trial NCT05896527?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 229 participants. The study started on 2023-05-02. Estimated completion is 2024-03-25.

What conditions does trial NCT05896527 study?

This clinical trial studies the following conditions: Plaque Psoriasis.

What interventions are being tested in trial NCT05896527?

The interventions under investigation include: Placebo (OTHER), DC-806 (DRUG).

Who is sponsoring clinical trial NCT05896527?

This trial is sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05896527 being conducted?

This trial has 20 study locations across California, Florida, Indiana, Kentucky, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Plaque Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Plaque Psoriasis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.